NextCure, Inc.
NextCure, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing targeted cancer therapies, including antibody-drug conjugates. Its pipeline includes SIM0505 and LNCB74, and the company also maintains a dedicated manufacturing facility to support clinical development.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaDevelopment of antibody-drug conjugate oncology candidates for patients with unmet need.
Use of licensed ADC technology to develop additional proprietary antibody-based candidates.
Biology, biomarker, and tumor microenvironment research used to identify targets and candidates.
Asiakkaat
NextCure does not currently sell commercial products; its work is directed toward future patients with cancer, especially those who do not respond to existing therapies. In the development phase, its counterparties are research partners, contract manufacturers, clinical trial sites, regulators, and potential future healthcare providers and payors if products are approved.
Patients with cancers that do not respond to current therapies; they are the intended beneficiaries of approved products.
Hospitals and physicians that enroll patients and administer study protocols for SIM0505, LNCB74, and other candidates.
Third parties that manufacture ADC intermediates and drug product or support clinical supply.
Oncologists, hospitals, and insurers that would influence adoption and reimbursement after approval.
Partners that may provide upfront fees, development support, or commercialization rights in selected territories.
Strategia
NextCure’s strategy is to advance SIM0505 and LNCB74 through clinical development and, if successful, toward regulatory approval and commercialization. The company also seeks external capital and potential collaborations or licensing arrangements to fund development and extend runway while preserving optionality across its pipeline.
Clinical progress is the main value driver for a company without commercial revenue.
Development programs require capital before any product revenue can be generated.
Partnerships and licensing can broaden resources and reduce single-asset dependence.
ADC programs require reliable clinical supply and future commercial scalability.
Maantiede
NextCure is headquartered in the United States and conducts its core research, development, and corporate activities there. Its licensed SIM0505 rights exclude China, Hong Kong, Macau, and Taiwan, where the licensor retains rights, while manufacturing and clinical supply may also involve third-party facilities outside the U.S.
Riskit
NextCure faces the typical risks of a clinical-stage biotech company: no approved products, dependence on clinical success, and ongoing need for external capital. Its pipeline also depends on third-party CROs and CDMOs, regulatory approvals, and access to specialized manufacturing capacity, which can be disrupted by operational, geopolitical, or trade-related issues.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Korkea
Pipeline value depends on proving safety and efficacy in human studies.
Kohdistuu - Financing riskVaikutus: KriittinenTodennäköisyys: Korkea
The company has no product sales and must raise capital to continue operations.
Kohdistuu - Third-party manufacturing and trial executionVaikutus: KorkeaTodennäköisyys: Korkea
CROs and CDMOs control key steps in development and supply.
Kohdistuu - Regulatory and healthcare complianceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Drug approval, promotion, and commercial arrangements are heavily regulated.
Kohdistuu - Foreign manufacturing and trade restrictionsVaikutus: Keskitaso
Some manufacturing is tied to non-U.S. facilities and counterparties.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätR&D costs depend on estimated vendor work performed but not yet invoiced.
Vaikutus: Can shift expense recognition between periods
Equity awards require fair value estimates and can materially affect operating expense.
Vaikutus: Affects G&A and R&D expense levels
Management must evaluate whether available cash is sufficient to fund operations.
Vaikutus: Important for liquidity disclosure and investor interpretation
The company has not commercialized products, so revenue is limited to collaboration-related items when present.
Vaikutus: Reported results are dominated by operating expenses and financing activity
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Xencor Inc
XNCR · Pharmaceutical Preparations
OnKure Therapeutics, Inc.
OKUR · Pharmaceutical Preparations
NovoCure Ltd
NVCR · Surgical & Medical Instruments & Apparatus
NovoCure Ltd develops and commercializes Tumor Treating Fields (TTFields) therapy, a non-invasive cancer treatment delivered through portable medical devices and arrays worn by patients.
Oric Pharmaceuticals, Inc.
ORIC · Pharmaceutical Preparations
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance.
Corbus Pharmaceuticals Holdings, Inc.
CRBP · Pharmaceutical Preparations
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Päivitetty: 24.9.2026